Cintredekin besudotox

Summary

Cintredekin besudotox (IL‑13‑PE38QQR) is an investigational recombinant fusion toxin that couples human interleukin‑13 to a truncated Pseudomonas exotoxin. It is designed for intracerebral convection‑enhanced delivery (CED) to target glioblastoma multiforme (GBM) and other malignant gliomas that over‑express IL‑13 receptor alpha‑2.

Mechanism of Action

The IL‑13 moiety of cintredekin besudotox binds with high affinity to IL‑13Rα2, a receptor markedly over‑expressed on GBM cells but scarce in normal brain. After receptor‑mediated internalisation, the PE38QQR exotoxin fragment catalyses ADP‑ribosylation of elongation factor‑2, halting protein synthesis and inducing rapid apoptotic cell death. Normal neural and immune cells lacking the receptor are largely spared, providing a tumour‑selective cytotoxic effect.

What the Research Shows

Pre‑clinical work demonstrated potent in‑vitro killing of glioma cell lines and tumour regression in animal models, while sparing normal brain tissue. Early phase I/II trials reported that CED of cintredekin besudotox was feasible and generally well tolerated, with median overall survival modestly longer than historical controls (≈11 months in an efficacy‑evaluable cohort). A phase III PRECISE trial compared CED cintredekin besudotox with Gliadel wafers in recurrent GBM; no significant survival advantage was observed (median 9.1 vs 8.8 months). Higher rates of pulmonary embolism were noted in the cintredekin arm. A phase I safety study in newly diagnosed malignant gliomas combined CED with radiation ± temozolomide, showing acceptable toxicity but dose‑limiting seizures and aphasia at the higher infusion concentration.

Reported Benefits

Cintredekin besudotox exploits the selective over‑expression of IL‑13Rα2 on GBM cells, enabling targeted delivery of a potent toxin while limiting systemic exposure. Early clinical experience suggested a tolerable safety profile and a possible modest extension of survival compared with historical benchmarks, supporting its concept as a biologically directed intracerebral therapy.

Limitations of the Evidence

Phase III data failed to demonstrate a survival benefit over the approved carmustine wafer, and technical challenges of CED—such as uneven drug distribution, backflow, and catheter placement—may have limited efficacy. The higher incidence of pulmonary embolism and dose‑limiting neurologic events raise safety concerns. Evidence remains limited to a few early‑phase trials, and optimal dosing and delivery parameters have not been established.

Safety Considerations

Overall adverse‑event rates were comparable to Gliadel wafers, but pulmonary embolism occurred more frequently with cintredekin besudotox (8 % vs 1 %). Neurologic toxicities—fatigue, gait disturbance, nystagmus, confusion—were common; higher infusion concentrations were associated with seizures and aphasia. No severe hematologic toxicity was reported. Monitoring for thromboembolic events and neurologic status is advised during and after infusion.

How It Is Administered

Cintredekin besudotox is administered exclusively via convection‑enhanced delivery. After surgical resection, 2–4 stereotactically placed intraparenchymal catheters infuse the drug over 96 hours at a defined concentration (e.g., 0.25–0.5 µg/mL). The infusion is pressure‑driven to distribute the toxin through the peritumoral brain tissue.

Routes of Administration

Goals & Uses

• Treatment of recurrent glioblastomaOncologyModerate

Contraindications

• Known hypersensitivity to Pseudomonas exotoxinAllergyHigh

Adverse Effects

• HeadacheNeurologicCommonPain in the head or upper neck
• Intracranial hemorrhageNeurologicalUncommon
• Cerebral edemaNeurologicalCommon

Drug Interactions

• CorticosteroidsLow

Population Constraints

• Pediatric patientsAgeRelative

Regulatory Status

• European UnionInvestigationalClinical trial status; no marketing authorization
• United StatesInvestigationalInvestigational New Drug (IND) application; not FDA‑approved

Evidence & Sources

• Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
  Journal ArticleModerateKunwar S, et al.2010-01-01T00:00:00.000000Z
• A comprehensive outlook on intracerebral therapy of malignant gliomas
  Journal ArticleModerateBuonerba C, et al.2011-01-01T00:00:00.000000Z
• The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy
  Journal ArticleModerateShimamura T, Husain SR, Puri RK2006-01-01T00:00:00.000000Z
• Cintredekin besudotox in treatment of malignant glioma
  Journal ArticleModerateMut M, et al.2008-01-01T00:00:00.000000Z
• Technology evaluation: cintredekin besudotox, NeoPharm/Nippon
  Journal ArticleModerateRainov NG, Söling A2005-01-01T00:00:00.000000Z
• Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results
  Journal ArticleModerateVogelbaum MA, et al.2007-01-01T00:00:00.000000Z

Frequently Asked Questions